Nonsteroidal, antiinflammatory drug-induced gastrointestinal injuries and related adverse reactions: Epidemiology, pathogenesis and management

Saudi Journal of Gastroenterology

Volumn 13, Issue 3, 2007, Pages 107-113

  Al Mofleh, Ibrahim A ^a,b   Al Rashed, Rashed S ^a  

^a KING SAUD UNIVERSITY   (Saudi Arabia)

^b KING KHALID UNIVERSITY HOSPITAL   (Saudi Arabia)

Author keywords

Adverse reactions; Epidemiology; Gastrointestinal injuries; Management; Nonsteroidal antiinflammatory drugs; Pathogenesis

Indexed keywords

EID: 34547475590     PISSN: 13193767     EISSN: None     Source Type: Journal    
DOI: 10.4103/1319-3767.33460     Document Type: Article

References (98)

1. Einarson TR. Drug related hospital admissions. Ann Pharmacother 1993;27:832-40.
2. Hadjibabie M. Rastkari N, Rezaie A, Abdollahi M. Hie adverse drug reaction in the gastrointestinal tract: An overview. Indian J Pharmacol 2005;1:1-8.
3. Hawkey CJ, Wight NJ. Clinician's Manual on NSAIDs and complications. Life Science Communications Ltd: London; 2001.
4. Laine L. Approach to nonsteroidal anti-inflammatory drug use in the high-risk patient. Gastroenterology 2001;120:595-606.
5. Wolfe M. NSAIDs and the gastrointestinal mucosa. Hosp Pract 1996:37-47.
6. Graumlich JF. Preventing gastrointestinal complications of NSAIDs. Postgrad Med 2001:109:117-28.
7. Sheen CL, MacDonald TM. Gastrointestinal side effects of NSAIDs pharmacoeconomic applications. Expert Opin Pharmacother 2002;3:265-9.
8. MS (International Medical Statistics) Publication. Pharmaceutical Database Division 1990, IMS Ltd. Plymouth Meeting, Pennsylvania and IMS World Medical Review: LIKand IMS America; 1989.
9. Dalen JE. Aspirin to prevent heart attack and stroke: What is the right dose? Am J Med 2006;119:198-202.
10. Giardiello FM, Hamilton SR, Krush A, Piantadosi S, Hylind LM, Celano P, et al. treatment of colonic and rectal adenomas with sulindac in familial adeomatous polyposis. N Engl J Med 1993;328:1313-6.
11. Stewart WF, Kawas C, Corrada M, Metter EJ. Risk of Alzheimer disease and duration of NSAID use. Neurology 1997;48:626-32.
12. Ofman JJ, Maclean CH, Straus WLMorton SC, Berger ML, Roth EA, et al. Meta-analysis of dyspepsia and nonsteroidal anti-inflammatory drugs. Arthritis Rheum 2003;49:508-18.
13. Hawkey CJ. Nonsteroidal anti-inflammatory drug gastropathy. Gastroenterology 2000;119:521-35.
14. Laine L Proton pump inhibitor co-therapy with nonsteroidal anti-inflammatory drugs-nice or necessary? Rev Gastroenterol Disord 2004;4:33-41.
15. Hawkey CJ. Nonsteroidal anti-inflammatory drugs and peptic ulcer. HMJ 1990:300:278-84.
16. Halter F, Tarnawski AS, Schmassmann A, Peskar BM. Cyclooxygenase 2-implications on maintenance of gastric mucosal integrity and ulcer healing: controversial issues and perspectives. Gut 2001:49:443-53.
17. Hallas J. Lauristen J, Villadsen HD, Gram LE Nonsteroidal anti-inflammatory drugs and upper gastrointestinal bleeding, identifying high-risk groups by excess risk estimates. Scand J Gastroenterol 1995:30:438-44.
18. Pilotto A, Di Mario F, Franceschi M, Leandro G, Battaglia G, Germana B, et al. Pantoprazole versus one week Helicobacter pylori eradication therapy for the prevention of acute NSAID-related gastroduodenal damage in elderly subjects. Aliment Pharmacol Ther 2000;14:1077-82.
19. Singh G, Triadafilopoulos G. Epidemiology of NSAID induced gastrointestinal complications. J Rheumatol 1999;26:18-24.
20. Langman MJ. Ulcer complications associated with anti-inflammatory drug use. What is the extent of the disease burden? Pharmacoepidemiol Drug Safety 2001;10:13-9.
21. Hawkey CJ. Langman MJ. Non-steroidal anti-inflammatory drugs: Overall risk and management. Complementary role for COX-2 inhibitors and proton pump inhibitors. Gut 2003;52:600-8.
22. Bjarnason I, Hyllar J, MacPherson AJ, Russel AS. Side effects of nonsteroidal anti-inflammatory drugs on the small and large intestine in humans. Gastroenterology 1993;104:1832-47.
23. Ksw PY, Terrnaine WJ. Nonsteroidal anti-inflammatory drugs-induced enteropathy: Case discussion and review of the literature. Miyo Clin Proc 1995;70:55-61.
24. Kaufman HJ, Taubin HL. NSAID activate quiescent inflammatory bowel disease. Ann Intern Med 1987;107:513-6.
25. Gibson GR, Whitacre EB, Ricotti CA. Colitis induced by nonsteroidal anti-inflammatory drugs. Arch Intern Med 1992;152:625-32.
26. Chan FK, Lawrence CT, Hung MD, Bing Y, Suen RN, Justin CY, et al. Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent, ulcer bleeding in patients with arthritis. N Engl J Med 2002:347:2104-10.
27. Hippisley-Cox J, Coupland C, Logan R. Risk of adverse gastrointeslinal outcomes in patients taking cyclo-oxygenase-2 inhibitor or conventional non-steroidal anti-inflammatory drugs: Population based nested case-control analysis. Br Med J 2005:331:1310-6.
28. Peskar BM, Maricic N. Role of prostaglandins in gastroprotection. Dig Dis Sci 1998;43:23-9.
29. Toma W, Hiruma-Lima, Guerro RO, Souza Brito ARM. Preliminary studies of Mammea Americana L (Guttifera) bark/latex extract point to an effective antiulcer effect on gastric ulcer models in mice. Phytomedicine 2005;12:345-50.
30. Lichtenberger LM. The hydrophilic barrier properties of gastrointestinal mucus. Ann Rev Physiol 1995;57:565-83.
31. Hogben CA, Schanker LS, Tocco DJ, Brodie BB. Absorption of drugs from the stomach. II. The human. J Pharmacol Exp Ther 1957;120:540-5.
32. Fiorucci S, Antonelli E, Morelli A. Mechanism of non-steroidal anti-inflammatory drug-gastropathy. Digest Liver Dis 2001;33:35-43.
33. Blandizzi C, Fornai M, Colucci R, Natale G, Lubrano Wasslle C, et al. Lansoprazole prevents experimental gastric injury induced by non-steroidal anti-inflammatory drugs through a reduction of mucosal oxidative damage. World J Gastroenterol 2005:11:4052-60.
34. Vane JR, Botting RM. Mechanism of action of anti-inflammatory drugs. Int J Tissue React 1998;20:3-15.
35. Whittle BJ. Gatrointestinal effect of nonsteroidal anti-inflammatory drugs. Fundam Clin Pharmacol 2003;17:301-13.
36. Hawkey CJ. Nonsteroidal anti-inflammatory drug gastropathy. Gastroenterology 2000:119:521-35.
37. Wallace JL. Pathogenesis of NSATD-induced gastroduodenal mucosal injury. Best Pract Res Clin Gastroenterol 2001:15:691-703.
38. Wallace JL, Granger DN. The cellular and molecular basis of gastric mucosal defence. FASBB J 1996;10:731-40.
39. Wallace JL, Tigley AW. Review article: New insights into prostaglandin and mucosal defense. Aliment Pharmacol Ther 1995;91:227-35.
40. Miller TA, Kuo YJ, Schmidt KL, Shambour LL. Nonprotein sulfhydryl compounds in canine gastric mucosa: Effects of PGE2 and ethanol. Am J Physiol 1985;249:137-44.
41. Sabo S. Trier JS, Frank PW. Sulfhydryl compounds may mediate gastric protection. Science 1981;214:200-2.
42. Al Mofleh IA, Alhaider AA, Mossa JS, Al-Sohaibani MO, Qureshi S, Rafatullah S. Antisecretagogue, antiulcer and cytoprotective effects of 'Peppermint' Mentha peperritia L in laboratory animals. J Med Sci 2006;6:930-6.
43. Nasuti C, Gabianelli R, Flcioni G, Cantalamessa F. Antioxidative and gastroprotective activities of anti-inflammatory formulations derived from chestnut honey in rats. 2006;26:130-7.
44. Rainsford KD. Gastric ulcerogenecity of non-steroidal anti-inflammatory drugs in mice with mucosa sensitized by cholinomimetic treatment. J Pharmacol 1978;39:669-72.
45. Al Mofleh IA, Alhaider AA, Mossa JS, Al-Sohaibani MO, Qureshi S, Rafatullah S. Antigastric ulcer studies on 'Saffron' Croats sativum L in rats. Pak J Biol Sci 2006:9:1009-13.
46. Lanza FL. A review of gastric ulcer and gastroduodenal injury in normal volunteers receiving aspirin and other non-steroidal anti-inflammatory drugs. Scand J Gastrenterol 1989;163:24-31.
47. Gabriel SE, Jaakkimainen L, Bombardier C. Risk for serious gastrointestinal complications related to use of non-steroidal anti-inflammatory drugs: Ameta-analysis. Ann Intern Med 1991;115:787-96.
48. Kurata JH, Abbey DE. The effect of chronic aspirin use on duodenal and gastric ulcer hospitalization. J Clin Gastroenterol 1990:12:260-6.
49. Robert A, Nezamis JE, Lancaster C, Hanchar AJ. Cytoprotection by prostaglandins in rats: Prevention of gastric necrosis produced by alcohol, HCL NaOH, hypertonic NaCL, and thermal injuriy. Gastroenterology 1979;77:433-43.
50. Whittle BJ, Lopez-Belmonte J. Actions and interactions of endothelins, prostacyclin and nitric oxide in the gastric mucosa. J Physiol Pharmacol 1993;44:91-107.
51. Jimenez D. Martin MJ. Pozo D, Alarcon C, Esteban J. Brusighini L et al. Mechanisms involved in protection afforded by L-Arginine in ibuprofen-induced gastric damage: Role of nitric oxide and prostaglandins. Dig Dis Sci 2002:47:44-53.
52. Kubes P, Zusuki P, Granger DN. Nitric oxide: An endogenous modulator of leukocyte adhesion. Proc Nat. Acad Sci USA 1991:88:4651-5.
53. May GR. Grook P, Moore KP, Page CP. The role of nitric oxide as endogenous regulator of platelet and neutrophile aactivation within the pulmonary circulation in the rabbit. Br J Pharmacol 1991;102:759-63.
54. Borelli F, Izzo AA. The plant kingdom as a source of anti-ulcer remedies Phytother Res 2000;14:581-91.
55. Pavelka K, Recker DR, Verburg KM. Vadecoxib is as effective as diclofenac in the management of rheumatoid arthritis with a lower incidence of gastroduodenal ulcers: results of a 26-week trial. Rheumatology 2003;42:1207-15.
56. Chan FK, Lawrence CT, Hung MD, Suen BX Justin CX Wu MD, et al. Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis. N Engl J Med 2002;347:2104-10.
57. Battistella M, Mamdami MM, Juurlink DN, Rabenck L. Laupacis A. Risk of upper gastrointestinal hemorrhage in wafarin users treated with nonselective NSAIDS or COX-2 inhibitors. Arch Intern Med 2005:165:189-92.
58. Chan FK, Sung JJ. Role of acid suppressants in prophylaxis of NSAID damage. Best Pract Res Clin Gastroenterol 2001:15:43345.
59. Rostom A, Wells G, Tugwell P, Welch V, Dube C, McGowan J. The prevention of chronic NSAID induced upper gastrointestinal toxicity: A Cochrane collaboration meta-analysis of randomized controlled trials. J Rheumatol 2000;27:2203-14.
60. Arcs JJ, Outt PE. Gastroprotective agents for the prevention of NSAID-induced gastropathy. Curr Pharm Des 1998;4:17-36.
61. Lancaster-Smith MJ. Jaderberg MF, Jackson DA. Ranitidine in the treatment of non-steroidal anti-inflammatory drug associated gastric and duodenal ulcer. Gut 1991;32:252-5.
62. O'Laughlin JC, Silvoso GK. Ivey KJ. Resistance to medical therapy of gastric ulcers in rheumatic disease patients taking aspirin. Adouble-blind study with cimetidine and follow-up. Dig Dis Sci 1982;27:976-80.
63. Walan A. Bader JP, Classen M. Lamers CB. Piper DW, Rutgerson K. et al. Effect of omeprazole and ranitidine on ulcer healing and relapse rates in patients with benign gastric ulcer. N Engl J Med 1989;320:69-75.
64. Romans ND. Tulassy Z, Juhasz L, Racz I, Howard JM, Van Rensburg CG. et al. Acomparison of Omeprazole with ranitidine for ulcers associated with nonsteroidal anti-inflammatory drugs. ASTRONAUT study group. N Engl J Med 1998;338:719-26.
65. Goldstein JL, Johanson JF, Suchower MA, Brown KA, Healing of gastric ulcers with esomeprazole versus ranitidine in patients who continued to receive NSATD therapy: A randomized trial. Au J Gastroenterol 2005;100:2650-7.
66. Hawkey CJ, Iangman MJ. Non-steroidal anti-inflammatory drags: overall risks and management. Complementary roles for COX-2 inhibitors and proton pump inhibitors. Gut 2003;52:600-8.
67. Graham DY, Agrawal NM Campbell DR, Haber MM Chilis C, Lukasik NL et al. NSAID Associated Gastric Ulcer Prevention Study Group. Ulcer prevention in long-term users of nonsteroidal anti-inflammatory drugs: Results of a double-blind, randomized, multicenter, active- and placebo-controlled study of misoprostol vs lansoprazole. Arch Intern Med 2002;162:169-5.
68. Suzuki M, Mori M, Miura S, Suematsu M, Fukumura D, Kimura H et al. Omeprazole attenuates oxygen-derived free radical production from human neutrophils, Free Radical Biol Med 1996:21:727-31.
69. Wandall JH. Effects of omeprazole on neutrophil Chemotaxis, superoxide production, degranulation and translocation of cytochroin b245. Gut 1992;33:617-21.
70. Iapenna D, de Giola S, Ciofani G, Festi D, Cuccurullo E Antioxidant properties of omeprazole. FEBS Lett 1996:382:189-92.
71. Alhaider AA, Al Mofleh IA, Mossa JS, Al Sohaibani MO, Qureshi S, Rafatullah S. Pharmacological and safety evaluation studies on "Cardamom" Elettaria cardainoinum: An important ingredient of Gahwa (Arabian coffee). Arab J Pharmacol 2005:3:47-57.
72. A Mofleh IA. Alhaider AA, Mossa JS, Al-Sohaibani MO, Rafatullah S, Qureshi S. Protection of gastric mucosal damage by Coriandnm sativum L Pretreatment in Wistar albino rats. Envirom Toxicol Pharmacol 2006:22:64-9.
73. Al Mofleh IA, Alhaider AA, Mossa JS, Al-Sohaibani MO, Qureshi S, Rafatullah S. Pharmacological studies on Clove' Eugenia caryophyllata. PHCOG Mag 2005;1:105-9.
74. Al Mofleh IA, Al Haider AA, Mossa JS, Al-Sohaibani MO. Rafatullah S. Qureshi S. Inhibition of gastric mucosal damage by Piper Nigrum (Black pepper) pretreatment in Wistar Albino Rats. PHCOGMag 2005;1:64-8.
75. Alhaider AA, Al Mofleh IA, Mossa JS, A-Sohaibani MO. Rafatullah S, Qureshi S. Effect of Carum carvi on experimentally induced gastric mucosal damage in Wistar Albino rats, Int J Pharmacol 2006;2:309-15.
76. Huang JQ, Sridhar S, Hunt RH. Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic ulcer disease: A meta-analysis. Lancet 2002;359:14-22.
77. Paptheodoridis GV, Papadelli D, Giolongitas E, Vassilopoulos D, Mentis A Hadziyannis SJ. Effect of Helioobacter pylori infection on lhe risk of upper gastrointestinal bleeding in users of nonsteroidal anti-inflammatory drugs. An J Med 2004;116:601-5.
78. Brakin J. The relation between Helicobacter pylori and nonsteroidal anti-inflammatory drugs. An J Med 1998;105:22-7.
79. Shirin H, Moss SE Kancherla S, Kancherla K Holt PR Weinstein B, et al. Non-steroidal anti-inflammatory drugs have bacteriostatic and bactericidal activity against Helicobacter pylori. J Gastroenterol Hepatol 2006;21:1388-93.
80. Taha AS, Nakshabendi I, Lee FD, Sturrock RD. Roussell RL Chemical gastritis and Helicobacter pylori-related gastritis in patients receiving non-steroidal anti-inflammatory drugs: Comparison and correlation with peptic ulceration. J Clin Pathol 1992:45:135-9.
81. Laine L, Marin-Sorensen M, Weinstein WM. Nonsteroidal anti-inflammatory drug associated gastric ulcer do not. require Helicobacter pylori for their development. Am J Gastroenterol 1992:87:1398402.
82. Cullen DJ, Hawkey GM, Greenwood DC, Humphreys H, Shepherd V, Logan RE et al. Peptic ulcer bleeding in the elderly: Relative roles of Helicobacter pylori and non-steroidal anti-inflammatory drugs. Gut 1997;41:459-62.
83. Ng TM, Fock KM, Khor JL, Teo EK, Sim CS, Tan AL, et al. Non-steroidal anti-inflammatory drugs, Helicobacter pylori and bleeding gastric ulcer. Aliment Pharmacol Ther 2000:14:203-9.
84. Frezza M. Gorji N, Melato M. The histology of non-steroidal anti-inflammatory drug induced gastroduodenal damage: correlation with Helicobacter pylori, ulcers and hemorrhagic events. J Clin Pathol 2001;54:521-5.
85. Mousavi S, Toussy J, Zahmatkesh M. NSAIDs and Helicobacter pylori association in patients with bleeding peptic ulcers. Indian J Gastroenterol 2006;25:216.
86. Calvet X, Grataros J, Font J, Larrosa M, Sanfeliu I, Roque M. Helicobacter pylori does not play a part, in the dyspeptic complaints of rheumatology patients receiving long term treatment with non-steroidal antiinflammatory drugs. Ann Rheura Dis 2002;61:641-3,
87. Laine L The effect of Helicobacter pylori infection on nonsteroidal anti-inflammatory drug-induced upper gastrointestinal tract injury. Aliment Pharmacol Ther 2002;16:34-9.
88. Labenz J, Hum AL Bolten WW, Dragosics B, Rosch W, Stolte M, et al. Primary prevention of diclofenac associated ulcers and dyspepsia by omeprazole or triple therapy in Helicobacter pylori positive patients: A randomized, double blind, placebo controlled, clinical trial. Gut 2002;51:329-35.
89. Sarosiek J, Sloiniani A, Slomiani BL Evidence of weakening of gastric mucus integrity by Campylobacter pylori. Scand J Gastroenterol 1988:23:585-90.
90. Taha AS, Angerson W Nakshabendi L Beekman H, Morran C, Sturrck RD, et al. Gastric and duodenal mucosal blood flow in patients receiving non-steroidal anti-inflammatory drugs-influence of age, smoking, ulceration and Helicobacter pylori. Aliment Pharmacol Ther 1993;7:41-5.
91. Schaverbeke T, Broutet N, Zerbib F, Combe B, Bertin R Lamouliattc H, et al. Should we eradicate Helicobacter pylori before prescribing an NSAID? Results of a placebo-controlled study. Am J Gastroenterol 2005;100:2637-43.
92. Brzozowski T, Konturek PC, Sliwowski Z, Kwiecien S. Drozdowicz D, Pawlik M, et al. Interaction of nonsteroidal anti-inflammatory drugs (NSAID) with Helicobacter pylori in the stomach of humans and experimental animals. J Physiol Pharmacol 2006;57:67-79.
93. Scheiman JM andekar RR Chernew ME, Eendrick AM Helicobacter pylori screening for individuals requiring chronic NSAID therapy: Adecision analysis. Aliment Pharmacol Ther 2001:15:63-71.
94. Papatheodoridis GV, Archimandritis AJ. Role of Helicobacter pylori in aspirin or non-steroidal anti-inflammatory drug users. World J Gastroenterol 2005:11:3811-6.
95. Chan FK, To KF, Wu JC, Ming MY, Leung WK Kwok T, et al. Eradication of Helicobacter pylori and risk of peptic ulcer in patients starting long-term treatment with non-steroidal anti-inflammatory drugs: A randomized trial. Lancet 2002;359:9-13.
96. Hunt RH, Bazzoli F Should NSAID/low-dose aspirin takers be tested routinly for H. pylori infection and treated if positive? Implication for primary risk of ulcer and ulcer relapse after initial healing. Aliment. Pharmacol Ther 2004:19:9-16.
97. Nergara M, Catalan M, Gisbert JP, Calvet X Meta-analysis: Role of Helicobacter pylori eradication in the prevention of peptic ulcer in NSAID users. Aliment Pharmacol Ther 2005;21:1411-8.
98. Dajani A Dhain R. El-Sahhar M, Subeih S, El Sheikh S, Mansour A er al. Importance of Helicobacter pylori eradication for maintenance of remission of drug associated peptic ulcer disease. Saudi J Gastroenterol 2006:12:16-20.